An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer

Magnetic Resonance Materials in Physics, Biology and Medicine

Volumn 21, Issue 6, 2008, Pages 411-421

  Lenkinski, Robert E ^a   Bloch, B Nicolas ^a   Liu, Fangbing ^a   Frangioni, John V ^a   Perner, Sven ^b   Rubin, Mark A ^b   Genega, Elizabeth M ^a   Rofsky, Neil M ^a   Gaston, Sandra M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Gene expression; MRI; Prostate; Prostate cancer

Indexed keywords

CHOLINE KINASE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; NEUROPEPTIDE Y;

ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MAPPING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD; ANTIGENS, CD34; CHOLINE KINASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPEPTIDE Y; PROSTATIC NEOPLASMS; RECTUM; RNA, MESSENGER; RNA, NEOPLASM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57449120305     PISSN: 09685243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10334-008-0133-3     Document Type: Article

References (58)

1. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor EJ Feuer MJ Thun 2005 Cancer statistics, 2005 CA Cancer J Clin 55 10 30
2. G Andriole B Djavan N Fleshner F Schroder 2006 The case for prostate cancer screening with prostate-specific antigen Eur Urol Suppl 5 737 745
3. WJ Catalona DS Smith TL Ratliff JW Basler 1993 Detection of organ-confined prostate-cancer is increased through prostate-specific antigen-based screening Jama-J Am Med Assoc 270 948 954
4. JA Efstathiou MH Chen WJ Catalona DG McLeod PR Carroll JW Moul KA Roehl AV D'Amico 2006 Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality Urology 68 342 347
5. M Han AW Partin S Piantadosi JI Epstein PC Walsh 2001 Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer J Urol 166 416 419
6. IW van der Cruijsen-Koeter TH van der Kwast FH Schroder 2003 Interval carcinomas in the European randomized study of screening for prostate cancer (ERSPC)-Rotterdam J Natl Cancer Inst 95 1462 1466
7. AW Partin MW Kattan ENP Subong PC Walsh KJ Wojno JE Oesterling PT Scardino JD Pearson 1997 Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer-a multi-institutional update Jama-J Am Med Assoc 277 1445 1451
8. AW Partin LA Mangold DM Lamm PC Walsh JI Epstein JD Pearson 2001 Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium Urology 58 843 848
9. R Huzjan E Sala H Hricak 2005 Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer Nat Clin Pract Urol 2 434 442
10. R Alonzi AR Padhani C Allen 2007 Dynamic contrast enhanced MRI in prostate cancer Eur J Radiol 63 335 350
11. AR Padhani CJ Harvey DO Cosgrove 2005 Angiogenesis imaging in the management of prostate cancer Nat Clin Pract Urol 2 596 607
12. Casciani E, Gualdi GF (2006) Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging
13. M Dadiani E Furman-Haran H Degani 2006 The application of NMR in tumor angiogenesis research Prog Nuclear Magn Reson Spectrosc 49 27 44
14. N Hylton 2006 Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker J Clin Oncol 24 3293 3298
15. S Rehman GC Jayson 2005 Molecular imaging of antiangiogenic agents Oncologist 10 92 103
16. P Oehr 2006 'Omics'-based imaging in cancer detection and therapy Personal Med 3 19 32
17. W Negendank 1992 Studies of human tumors by MRS: a review NMR Biomed 5 303 324
18. E Segal CB Sirlin C Ooi AS Adler J Gollub X Chen BK Chan GR Matcuk CT Barry HY Chang MD Kuo 2007 Decoding global gene expression programs in liver cancer by noninvasive imaging Nat Biotechnol 25 675 680
19. SM Gaston MA Soares MM Siddiqui D Vu JM Lee DL Goldner MJ Brice JC Shih MP Upton G Perides J Baptista PT Lavin BN Bloch EM Genega MA Rubin RE Lenkinski 2005 Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule Nat Med 11 95 101
20. Y Rosen BN Bloch RE Lenkinski RL Greenman RP Marquis NM Rofsky 2007 3T MR of the prostate: reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension Magn Reson Med 57 898 904
21. BN Bloch NM Rofsky RH Baroni RP Marquis I Pedrosa RE Lenkinski 2004 3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils; Initial experience (1) Acad Radiol 11 863 867
22. CH Cunningham DB Vigneron M Marjanska AP Chen D Xu RE Hurd J Kurhanewicz M Garwood JM Pauly 2005 Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T Magn Reson Med 53 1033 1039
23. H Degani V Gusis D Weinstein S Fields S Strano 1997 Mapping pathophysiological features of breast tumors by MRI at high spatial resolution Nat Med 3 780 782
24. BN Bloch E Furman-Haran TH Helbich RE Lenkinski H Degani C Kratzik M Susani A Haitel S Jaromi L Ngo NM Rofsky 2007 Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging-initial results Radiology 245 176 185
25. E Furman-Haran H Degani 2002 Parametric analysis of breast MRI J Comput Assist Tomogr 26 376 386
26. A Schroeder O Mueller S Stocker R Salowsky M Leiber M Gassmann S Lightfoot W Menzel M Granzow T Ragg 2006 The RIN: an RNA integrity number for assigning integrity values to RNA measurements BMC Mol Biol 7 3
27. MA Rubin MP Zerkowski RL Camp R Kuefer MD Hofer AM Chinnaiyan DL Rimm 2004 Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements Am J Pathol 164 831 840
28. F Grizzi C Russo P Colombo B Franceschini EE Frezza E Cobos M Chiriva-Internati 2005 Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension BMC Cancer 5 14
29. A Rajesh FV Coakley J Kurhanewicz 2007 3D MR spectroscopic imaging in the evaluation of prostate cancer Clin Radiol 62 921 929
30. Coakley FV, Qayyum A, Kurhanewicz J (2003) Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 170: S69-S75; discussion S75-S76
31. KL Zakian K Sircar H Hricak HN Chen A Shukla-Dave S Eberhardt M Muruganandham L Ebora MW Kattan VE Reuter PT Scardino JA Koutcher 2005 Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy Radiology 234 804 814
32. T Haga 1971 Synthesis and release of (14 C) acetylcholine in synaptosomes J Neurochem 18 781 798
33. R Katz-Brull H Degani 1996 Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method Anticancer Res 16 1375 1380
34. Eliyahu G, Kreizman T, Degani H (2007) Phosphocholine as a biomarker of breast cancer: Molecular and biochemical studies. Int J Cancer
35. AR de Molina A Rodriguez-Gonzalez R Gutierrez L Martinez- Pineiro JJ Sanchez F Bonilla R Rosell JC Lacal 2002 Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers Biochem Biophys Res Commun 296 580 583
36. K Glunde MA Jacobs ZM Bhujwalla 2006 Choline metabolism in cancer: implications for diagnosis and therapy Expert Rev Mol Diagnos 6 821 829
37. SA Kwee MN Coel J Lim JHP Ko 2005 Prostate cancer localization with (18) fluorine fluorocholine positron emission tomography J Urol 173 252 255
38. SA Kwee H Wei I Sesterhenn D Yun MN Coel 2006 Localization of primary prostate cancer with dual-phase F-18-fluorocholine PET J Nuclear Med 47 262 269
39. SN Reske NM Blumstein B Neumaier HW Gottfried F Finsterbusch D Kocot P Moller G Glatting S Perner 2006 Imaging prostate cancer with C-11-choline PET/CT J Nuclear Med 47 1249 1254
40. J Folkman 2006 Angiogenesis Annu Rev Med 57 1 18
41. B Dome MJ Hendrix S Paku J Tovari J Timar 2007 Alternative vascularization mechanisms in cancer: pathology and therapeutic implications Am J Pathol 170 1 15
42. H Chaib EK Cockrell MA Rubin JA Macoska 2001 Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis Neoplasia 3 43 52
43. YM El-Gohary JF Silverman PR Olson YL Liu JK Cohen R Miller RS Saad 2007 Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma Am J Clin Pathol 127 572 579
44. N Soulitzis I Karyotis D Delakas DA Spandidos 2006 Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia Int J Oncol 29 305 314
45. K Walsh S Sriprasad D Hopster J Codd D Mulvin 2002 Distribution of vascular endothelial growth factor (VEGF) in prostate disease Prostate Cancer Prostat Dis 5 119 22
46. KK Rasiah JG Kench M Gardiner-Garden AV Biankin D Golovsky PC Brenner R Kooner F O'Neill G JJ Turner W Delprado CS Lee DA Brown SN Breit JJ Grygiel LG Horvath PD Stricker RL Sutherland SM Henshall 2006 Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis Cancer Epidemiol Biomarkers Prev 15 711 716
47. M Ruscica E Dozio M Motta P Magni 2007 Modulatory actions of neuropeptide Y on prostate cancer growth: role of MAP kinase/ERK 1/2 activation Adv Exp Med Biol 604 96 100
48. AJ Ekstrand R Cao M Bjorndahl S Nystrom AC Jonsson-Rylander H Hassani B Hallberg M Nordlander Y Cao 2003 Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing Proc Natl Acad Sci USA 100 6033 6038
49. EW Lee DS Grant S Movafagh Z Zukowska 2003 Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice Peptides 24 99 106
50. EW Lee M Michalkiewicz J Kitlinska I Kalezic H Switalska P Yoo A Sangkharat H Ji L Li T Michalkiewicz M Ljubisavljevic H Johansson DS Grant Z Zukowska 2003 Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles J Clin Invest 111 1853 1862
51. Z Zukowska DS Grant EW Lee 2003 Neuropeptide Y: a novel mechanism for ischemic angiogenesis Trends Cardiovasc Med 13 86 92
52. Z Zukowska-Grojec E Karwatowska-Prokopczuk W Rose J Rone S Movafagh H Ji Y Yeh WT Chen HK Kleinman E Grouzmann DS Grant 1998 Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium Circ Res 83 187 195
53. J Kitlinska 2007 Neuropeptide Y (NPY) in neuroblastoma: effect on growth and vascularization Peptides 28 405 412
54. J Kitlinska K Abe L Kuo J Pons M Yu L Li J Tilan L Everhart EW Lee Z Zukowska JA Toretsky 2005 Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors Cancer Res 65 1719 1728
55. MO Leach KM Brindle JL Evelhoch JR Griffiths MR Horsman A Jackson G Jayson IR Judson MV Knopp RJ Maxwell D McIntyre AR Padhani P Price R Rathbone G Rustin PS Tofts GM Tozer W Vennart JC Waterton SR Williams P Workman 2003 Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials Br J Radiol 76 S87 S91
56. PS Tofts 1997 Modeling tracer kinetics in dynamic Gd-DTPA MR imaging Jmri-J Magn Reson Imaging 7 91 101
57. PS Tofts G Brix DL Buckley JL Evelhoch E Henderson M Knopp HBW Larsson TY Lee NA Mayr GJM Parker RE Port J Taylor RM Weisskoff 1999 Estimating kinetic parameters from dynamic contrast-enhanced T-1-weighted MRI of a diffusable tracer: Standardized quantities and symbols Jmri-J Magn Reson Imaging 10 223 232
58. RL Camp GG Chung DL Rimm 2002 Automated subcellular localization and quantification of protein expression in tissue microarrays Nat Med 8 1323 1327